Corticosteroid Timing for Pulmonary Fibrosis Mitigation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19 primarily focus on acute infection, with limited knowledge on therapeutic targets for early infection, recovery, or long-term mitigation of pulmonary sequelae caused by SARS-CoV-2, which can lead to persistent structural and functional lung damage.
Innovation Solution
Administering effective amounts of corticosteroids, such as hydrocortisone, methylprednisolone, budesonide, and bronchodilators like salbutamol, at various timing schedules post-exposure or during recovery to mitigate pulmonary disease consequences, potentially combined with leukotriene antagonists and beta-agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids are administered to treat pulmonary disease from SARS-CoV-2 exposure, then pulmonary fibrosis progression is reduced and lung function is maintained, but the complexity of treatment timing and dosing schedules increases
Solution Approach 1:
The patent applies preliminary action by administering corticosteroids at specific time points following SARS-CoV-2 exposure, before full pulmonary damage occurs. The treatment protocol specifies administering corticosteroids within certain days post-exposure to prevent and reduce fibrosis progression, rather than waiting for symptoms to manifest. This proactive timing approach maintains lung function while managing the complexity through predefined treatment windows.
2Object-affected harmful factors
If corticosteroids are administered to mitigate pulmonary sequelae, then respiratory symptoms improve, but the difficulty of determining optimal treatment timing increases
Solution Approach 1:
The patent incorporates feedback mechanisms by monitoring patient response to corticosteroid treatment and adjusting dosing schedules accordingly. The treatment protocol includes evaluating symptom improvement and lung function changes to determine whether to continue, adjust, or discontinue corticosteroid therapy. This feedback approach addresses the difficulty of determining optimal timing by using patient-specific responses to guide treatment decisions.
3Adaptability or versatility
If multiple corticosteroid options are provided at different dosing schedules, then treatment adaptability increases, but the complexity of treatment protocols increases
Solution Approach 1:
The patent applies dynamics by providing a flexible treatment protocol that can be adjusted based on patient-specific factors such as disease severity, timing of exposure, and individual response. The protocol includes multiple dosing schedules (e.g., daily dosing for 5-10 days, or extended dosing for 2-4 weeks) that can be dynamically selected and modified. This dynamic approach increases adaptability while managing complexity through structured decision frameworks.
Data Source
AI summary
Disclosed herein are methods of treating a disease in a subject which is the consequence of previous exposure of the subject to a virus, particularly SARS-CoV-2, the method comprising administration of an effective amount of one or more agents to the subject.